Marcus is 58 and lives with a rare autoimmune condition; treatments for conditions like his often take a decade or more to reach a pharmacy shelf, and a huge chunk of that decade disappears into computers screening which drug candidates are even worth testing in a lab. A new qubit compression technique aims to shrink that wait. Researchers at Singapore’s A*STAR and the National University of Singapore packed three data points onto a single qubit instead of one, and used that trick to run a real drug-discovery calculation on IBM’s quantum hardware with roughly a third of the qubits a standard approach would need.
The team tackled molecular docking: the process of figuring out how a drug candidate physically fits into a target protein. Pharmaceutical companies run this calculation constantly, and it gets harder fast as molecules grow more complex. Classical computers already handle it well. Quantum hardware has struggled to keep up, mostly because today’s chips carry so few reliable qubits.
How the Qubit Compression Technique Works
Most quantum algorithms read one answer off each qubit. The Singapore team’s method, called Full-Basis Encoding, reads three. It measures a qubit’s spin along all three axes of the Bloch sphere instead of just one, and each axis carries its own independent piece of the answer.
- An 18-variable docking problem that normally needs 18 qubits ran on just 6.
- A 14-variable problem dropped from 14 qubits to 5.
- Both tests ran on IBM’s 156-qubit Heron processor and were checked against classical calculations.
Researchers reported the results, as The Quantum Insider covered in late August.
Why the Results Matter Beyond the Lab
The compressed method landed the correct answer in 74% of runs for one test molecule and 99% for the other. That is a meaningful result on hardware that still fights noise and short qubit lifetimes. Quantum chips today stay useful mainly when researchers squeeze more work out of the qubits already on hand. IonQ used that same logic to speed up real-time error decoding without adding new hardware.
For Marcus, faster screening is not an abstract efficiency gain. Techniques that let researchers screen more drug candidates on less hardware do not just save computing budgets. They shave real months off a process patients like him are waiting on.
This is not quantum advantage. Classical computers still solved both test problems just fine, and the researchers say so themselves. But it is a concrete step toward algorithms built for the noisy, qubit-scarce machines that actually exist today, rather than the much larger machines still years away.
A Race Against the Qubit Count
That distinction matters as the field races to grow qubit counts. Japan’s new neutral-atom quantum computer aims for 10,000 qubits within five years, and other labs are chasing similar targets. Techniques like Full-Basis Encoding make each of those qubits worth more, which shrinks the hardware a useful drug-discovery run actually requires.
Drug discovery has been one of quantum computing’s most-promised applications and one of its slowest to show real hardware results. A method that tests successfully on today’s IBM chips, instead of some future one, moves that promise a step closer to something pharmaceutical researchers can actually use.
For Marcus, the promise is simpler than any roadmap of future qubit tricks: every technique that squeezes more out of today’s hardware is one less year he might have to wait for the treatment he needs.